key: cord-0879077-lpvotb0n
authors: McCormick, Kevin D.; Mellors, John W.; Jacobs, Jana L.
title: Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2
date: 2020-11-27
journal: Curr Opin HIV AIDS
DOI: 10.1097/coh.0000000000000656
sha: 3e78b2f140ce1c9ab490b60c3ee96db366d5ae29
doc_id: 879077
cord_uid: lpvotb0n

In response to the HIV–AIDS pandemic, great strides have been made in developing molecular methods that accurately quantify nucleic acid products of HIV-1 at different stages of viral replication and to assess HIV-1 sequence diversity and its effect on susceptibility to small molecule inhibitors and neutralizing antibodies. Here, we review how knowledge gained from these approaches, including viral RNA quantification and sequence analyses, have been rapidly applied to study SARS-CoV-2 and the COVID-19 pandemic. RECENT FINDINGS: Recent studies have shown detection of SARS-CoV-2 RNA in blood of infected individuals by reverse transcriptase PCR (RT-PCR); and, as in HIV-1 infection, there is growing evidence that the level of viral RNA in plasma may be related to COVID disease severity. Unlike HIV-1, SARS-CoV-2 sequences are highly conserved limiting SARS-CoV-2 sequencing applications to investigating interpatient genetic diversity for phylogenetic analysis. Sensitive sequencing technologies, originally developed for HIV-1, will be needed to investigate intrapatient SARS-CoV-2 genetic variation in response to antiviral therapeutics and vaccines. SUMMARY: Methods used for HIV-1 have been rapidly applied to SARS-CoV-2/COVID-19 to understand pathogenesis and prognosis. Further application of such methods should improve precision of therapy and outcome.

In response to the COVID-19 pandemic, researchers across the globe have collectively shifted focus to the common goal of understanding the newly emerged SARS-CoV-2. HIV-1 researchers have accumulated nearly 40 years of experience studying an epidemic caused by a newly emerged viral pathogen, uniquely positioning them to quickly respond to a new viral pandemic. Many methods and technologies used during the HIV-1 epidemic can and have been applied to understanding the SARS-CoV-2 pandemic. In the following review, we discuss how molecular technologies developed for HIV-1 have been applied successfully and swiftly to the study of SARS-CoV-2.

Early in the AIDS epidemic disease was diagnosed and monitored clinically and by lymphocyte counts. Once HIV-1 was identified as the causative agent of AIDS [1, 2] , tests were developed to diagnose infection serologically and quantify HIV-1 RNA in blood [3] [4] [5] . The importance of quantifying HIV-1 RNA in plasma (also referred to as viral load) for prognosis was then demonstrated [6, 7] and it soon became routine practice to measure viral load for disease staging and assessing response to treatment ( Table 1 ). The importance of viral load as a marker of treatment failure and emergence of drug resistance from a highly diverse viral population became clear with the discovery of more potent inhibitors of viral replication. Indeed, the importance of viral load in disease monitoring became so widely accepted that the WHO recommended implementation of viral load testing for monitoring individuals on antiretroviral therapy (ART) in resource-limited settings in 2010 [8] . As viral load monitoring has become more important automated platforms have increased the ease and throughput of testing. Roche, Abbott, Hologic, and Cepheid offer FDA-cleared nucleic acid amplification-based HIV-1 RNA quantification tests on automated platforms that are widely used across the world (Table 1) .

Monitoring HIV-1 RNA levels below the limit of quantitation of commercial assays has become an important endpoint for many studies aimed at HIV cure. This is because, although ART results in logarithmic decreases in viral load, assays capable of detecting single copies of HIV-1 RNA have shown that the majority of those on ART have detectable HIV-1 RNA in the range of 1-3 cps/ml [9] [10] [11] [12] [13] [14] [15] [16] [17] . Studies of decay dynamics of virus in plasma have given important insights into disease progression and treatment, including the existence of a longlived viral reservoir [12, 13, 15] . In addition, clearance of low-level persistent viremia may be a marker for HIV cure so great focus has been given to detection of viral RNA below 20 cps/ml. Some iteration of manual reverse transcriptase PCR (RT-PCR) assays have been used for most studies of persistent lowlevel viremia (Table 1) [9, 14, 16] . Since manual single copy assays are inherently low-throughput and technically difficult there have been recent efforts to adapt high-throughput commercial platforms for detection of low-level persistent viremia [18 & ,19]. Incorporating high throughput single copy assays will facilitate large studies aimed at clearing persistent viremia and achieving functional cure.

One of the largest and most critical efforts at the start of the COVID-19 pandemic was the search for a reliable, quick, and broadly available test for SARS-CoV-2 infection. Since the beginning of the HIV epidemic in the 1980s the field of molecular diagnostics has made tremendous strides, enabling the release of a molecular test for SARS-CoV-2 RNA very quickly after the sequence of the viral genome was made available [20 && ,21,22 & ,23] . In addition to significant technical advances in molecular diagnostics, the low genetic diversity of SARS-CoV-2 as compared with HIV-1 and other RNA viruses has also contributed to the quick release and implementation of molecular assays to detect SARS-CoV-2 RNA [24 && ]. Similar to HIV-1 the first SARS-CoV-2 molecular diagnostic tests developed were largely manual, but diagnostic companies quickly followed with their own high-throughput versions with varying amounts of automation, including Roche, Abbott, Hologic, and Cepheid (Table 1) . Importantly, these tests are designed to test respiratory specimens and are qualitative with some simply returning a positive or negative result. Others return a cycle threshold value, allowing approximation of levels of viral RNA in the sample. As the pandemic

An important breakthrough in HIV-1 science was the development of sensitive RT-PCR assays of plasma HIV-1 RNA to estimate prognosis, understand pathogenesis and identify effective treatments.

Improved HIV-1 RNA assays with single copy sensitivity have provided insights in HIV-1 persistence on antiretroviral therapy and can help guide efforts to eliminate HIV-1 reservoirs.

Until recently, detection of SARS-CoV-2 RNA by RT-PCR assays in nasopharyngeal and oropharyngeal samples have been the sole method for diagnosis of COVID-19.

Similar to HIV-1, quantification of SARS-CoV-2 RNA in plasma has been associated with disease severity and more sensitive assay may strengthen the association and provide further insights in disease pathogenesis and persistence.

Despite the limited genetic diversity of SARS-CoV-2 compared with HIV-1, the development of vaccines and therapeutics for COVID-19 will likely create the need for more sensitive sequencing methods to detect the emergence of minor populations of escape variants and to determine the linkage of mutations detected. 

Little focus has been given to the potential presence of virus in the blood (viremia) in most respiratory infections since primary target cells and general symptoms point to respiratory containment of infection. However, analyses of SARS-CoV-2 RNA in the nasopharynx have not shown consistent associations with symptomatic disease, including the severity of symptomatic disease [25] [26] [27] [28] [29] [30] . While the lack of consistent association is partly attributable to inconsistencies in sample collection [31] , variable viral replication kinetics in the upper respiratory tract over the infection course represent another possible explanation for the lack of consistent association between diagnostic test cycle threshold value and disease severity [32] . In addition, sampling of only the nasopharynx may miss contributions to disease caused by viral replication in the lower respiratory track or dissemination of virus through blood to extrapulmonary sites. Reports of both expanded receptor expression beyond the primary target cells in the lung and presence of virus in peripheral tissues such as the gastrointestinal (GI) tract, endothelium and central nervous system (CNS) may point to disseminated viral infection as an important contributor to severe disease [33] [34] [35] [36] [37] [38] [39] [40] [41] . Indeed, an unusually wide range of symptoms can accompany SARS-CoV-2 infection, including thromboses, loss of smell, vomiting, and diarrhea [37, [42] [43] [44] . Unlike HIV-1, current data do not suggest that SARS-CoV-2 replicates to a significant degree in peripheral blood cells; however, normal blood flow could provide a means for virus dissemination to extrapulmonary sites. Aside from a possible role in disease pathogenesis, blood-borne viral RNA could also be an important indicator of lung tissue breakdown leading to release of intact virions, viral proteins and nucleic acids, or infected cells into the bloodstream. Longitudinal analysis from patients across the spectrum of disease severity, including those with progressive disease during the observation period, is ongoing and is expected to provide additional insight into the usefulness of SARS-CoV-2 plasma RNAemia as a prognostic marker. In addition, it is possible that application of single copy assays to blood samples similar to those discussed above for HIV-1 will increase the frequency of SARS-CoV-2 RNA detection in less severe disease ( 

Applying sequencing analysis to HIV-1 has provided tremendous insight into its global spread, transmission patterns, pathogenesis, immune escape, diagnostics, and viral response to treatments including small molecules and neutralizing antibodies and by identifying mutations associated with viral drug resistance to ART. Although the initial epidemiology of HIV-1 and AIDS was based on serological studies, sequencing technologies provided rapid and new insights [52] [53] [54] , revealing large diversity between HIV-1 isolates, and it is now understood that HIV-1 has an extraordinarily high genetic variability with a mutation rate of 4 Â 10 À5 nucleotide per site per replication cycle [55] [56] [57] resulting in rapid adaptation to selective pressures. Because of the high mutation rates and highly divergent lineages, no vaccine exists to prevent the transmission of HIV-1.

In addition to applications for improving primer design for more accurate virus quantification, a major application of HIV-1 sequencing is to detect mutations in the virus that are associated with drug resistance. By identifying mutations in HIV-1 that may have been selected for in persons receiving ART or examining the effectiveness of ART regimens in individuals with viruses containing suspected drugresistance mutations, sequencing technology was used as a tool for establishing the most effective ART regimens [58] .

To this aim, first-generation Sanger-based sequencing technologies provided a foundation for the commercialization of clinical drug resistance assays, which have allowed clinicians to tailor treatment to an individual patient's mutational pattern. Although Sanger-technology was dependable for accurately identifying mutations associated with drug resistance in the majority (>20%) of viruses circulating in plasma from persons living with HIV-1, elucidating minor intraindividual variation required sequencing cDNA templates diluted to single copies, known as single-genome sequencing (SGS) [59] [60] [61] (Table 2) . Although SGS increased the sensitivity for minor variants over Sanger technology, it was limited by the number of sequencing reactions required for each patient. Next-generation sequencing (NGS) increased the throughput capacity and accuracy of sequencing by allowing for the simultaneous sequencing of thousands of copies of DNA in a single run. Multiplex amplified samples with unique index sequences greatly reduced the complexity of SGS allowing multiple amplified cDNA products in the same sequencing run. Subsequently the incorporation of cDNA barcoding into NGS increased the sensitivity for minor variant detection [62, 63] even more than SGS [i.e., ultrasensitive SGS (uSGS) [64] ] and was recently used to uncover rare mutations linked on the same HIV-1 genome [65] .

Since the first sequence of SARS-CoV-2 was generated [22 & ], more than 95 000 SARS-CoV-2 sequences have been deposited in the global initiative on sharing all influenza data (GISAID). Unlike HIV-1, which has high-level heterogeneity even within an infected individual with an estimated substitution rate of 0.8-1.7 Â 10 À3 per site per year [66] [67] [68] , SARS-CoV-2 sequences have a high-sequence identity with a substitution rate estimated to be 8.4 Â 10 À4 -1.1 Â 10 À3 per site per year at the population level [69] [70] [71] [72] . This conservation has largely been attributed to the exoribonuclease (ExoN) activity of the nonstructural protein 14 (nsp14) as it was demonstrated that wild-type SARS-CoV has a mutation rate of 9.0 Â 10 À7 substitutions per nucleotide per replication cycle [73] . However, a mutant form with an inactivating substitutions in nsp14 reduced the fidelity to 1.2 Â 10 À5 substitutions per nucleotide per replication cycle, strikingly similar to HIV-1 and other RNA viruses [73] [74] [75] . Significantly, it was shown that a common SARS-CoV-2 mutation 14408C>T that causes a P323L substitution in the RNA dependent RNA polymerase (nsp12) may also increase the mutation rate, suggesting that mutations in regions outside of the ExoN could also alter SARS-CoV-2 fidelity [76] .

In contrast to the complex HIV-1 classification systems, the conservation of SARS-CoV-2 required that slight differences in sequences were used to develop the three major nomenclature classification systems [77 && ] ( Table 3 ). The first two classification systems, GISAID and Nextstrain, are focused on investigating large scale diversity patterns of SARS-CoV-2 for understanding of patterns and determinants of the global spread by identifying clades that persist for at least several months and have significant geographic spread [78, 79] . The PANGOLIN lineage system is the third classification system and was developed to have short-term epidemiological significance by utilizing a more dynamic system for tracking active virus lineages [77 && ,78,80].

As with HIV-1, SARS-CoV-2 sequences have facilitated the investigation of transmission dynamics to guide public health action and to elucidate sequence conservation for the development of robust molecular diagnostic methods. For these reasons, SARS-CoV-2 whole genome sequencing (WGS) will continue to be essential in tracking the pandemic. In addition, as case studies have recently documented reinfections of SARS-CoV-2, the limited amount of sequence diversity in SARS-CoV-2 in any given gene region necessitates WGS for differentiating the first and second episodes by showing that each of the viruses belonged to a different lineages rather than a few mutations having been a consequence of RT-PCR or sequencing error [81, 82] . Although the sequence conservation in SARS-CoV-2 genomes has limited the application of sequencing technologies relative to HIV-1, selective pressures from both host immune as well as novel vaccine and therapeutic interventions are likely to drive novel mutations in SARS-CoV-2 in the future. The SARS-CoV-2 envelope glycoprotein or Spike mediates viral entry into host cells and is thus currently the major target for vaccine and monoclonal neutralizing antibody development. As such, Spike gene sequencing will be a key focus for identifying immune escape variants. Several studies have shown that patients infected with SARS-CoV-2 strains having Gly614 variant in Spike had on average lower RT-PCR cycle threshold values relative to individuals infected with Asp614 [83 & ,84] and it was also shown that the D614G substitution increases the infectivity in vitro [83 & ,85] . However, there has been no conclusive evidence that any of the emerging SARS-CoV-2 substitutions have resulted in a change in transmissibility or the disease severity of COVID-19 [24 && ]. There is also a growing body of evidence to suggest that deletions as well as mutations may be important for SARS-CoV-2 infection. For example, a deletion in Spike at the S1/S2 cleavage site that causes a premature stop codon after S1 was observed and it was speculated that this deletion may cause an increase in free S1 as a mechanism to mitigate the host response to SARS-CoV-2 infection and cause less severe disease [86] . Such deletions may also exist outside of Spike; in fact, a group recently showed that a 382-nucleotide deletion in SARS-CoV-2 ORF7b and ORF8 eliminates ORF8 transcription and, because there is a robust antibody response to ORF8, they suggest that it may be the result of immune-driven selection [69] .

It is possible that more sensitive sequencing approaches are needed, such as SGS or uSGS, to completely understand the intrapatient variation and consequences of SARS-CoV-2 mutations. In addition, as the selection of mutations through immunotherapy or vaccination will often come at the expense of fitness, genetic variants will likely exist at different frequencies depending on the 

a Pangolin lineages are also based upon phylogenetic evidence, but because they also factor in active local geographical outbreaks, they are too numerous for this Conflicts of interest J.W.M. is a consultant to Gilead Sciences and holds shares or share options in Co-Crystal Pharma, Inc., Abound Bio, Inc. and Infectious Disease Connect. K.D.M. and J.L.J. declare no conflicts of interest.

Papers of particular interest, published within the annual period of review, have been highlighted as:

Prebensen C, Hre PLM, Jonassen C, et al. SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19. Clin Infect Dis 2020; Epub ahead of print. Describes an association between plasma SARS-CoV-2 RNA levels and disease severity, but no association was found between nasopharynx swab SARS-CoV-2 RNA levels and disease severity.

& Veyer D, Kerneis S, Poulet G, et al. Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value. Clin Infect Dis 2020. Describes associations between presence and levels of SARS-CoV-2 RNA in plasma and disease severity and outcome. 50.

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)

Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS

NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection

Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection

Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay

Plasma viral load and CD4þ lymphocytes as prognostic markers of HIV-1 infection

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

Antiretroviral therapy for HIV infection in adults and adolescents recommendations for a public health approach: 2010 revision

Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy

Persistent HIV-1 viremia on antiretroviral therapy: measurement and mechanisms

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma

Continued slow decay of residual plasma viremia in HIV-1-infected adults on long term antiretroviral therapy

A simpler and more sensitive singlecopy HIV-1 RNA assay for quantification of persistent HIV-1 viremia in individuals on suppressive antiretroviral therapy

Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy

Automated, multi-replicate quantification of persistent HIV-1 viremia in individuals on antiretroviral therapy

Describes development of the first validated workflow for molecular detection of SARS-CoV-2 RNA

First case of 2019 novel coronavirus in the United States

First published sequence of SARS-CoV-2. They used an untargeted metagenomics sequencing approach

A novel coronavirus from patients with pneumonia in China

Informative essay on modeling the evolutionary epidemiology of SARS-CoV-2 in response to recent conclusions regarding the impact of emerging mutations on the transmissibility of SARS-CoV-2

Association of initial viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and symptoms

Temporal dynamics in viral shedding and transmissibility of COVID-19

Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea

Viral dynamics in mild and severe cases of COVID-19

SARS-CoV-2 viral load predicts COVID-19 mortality

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Suboptimal biological sampling as a probable cause of false-negative COVID-19 diagnostic test results

Kinetics of viral load and antibody response in relation to COVID-19 severity

SARS-CoV-2 productively infects human gut enterocytes

Multiorgan and renal tropism of SARS-CoV-2

Neuropathological features of Covid-19

Neuroinvasion of SARS-CoV-2 in human and mouse brain

COVID-19: the vasculature unleashed

Endothelial cell infection and endotheliitis in COVID-19

Detection of SARS-CoV-2 in different types of clinical specimens

Evidence for gastrointestinal infection of SARS-CoV-2

SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues

High prevalence of concurrent gastrointestinal manifestations in patients with severe acute respiratory syndrome coronavirus 2: early experience from California

COVID-19: gastrointestinal manifestations and potential fecal-oral transmission

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Relationship between serum SARS-CoV-2 nucleic acid(RNAemia) and organ damage in COVID-19 patients: a cohort study

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIVinfected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

Molecular cloning and primary nucleotide sequence analysis of a distinct human immunodeficiency virus isolate reveal significant divergence in its genomic sequences

Molecular cloning and characterization of the HTLV-III virus associated with AIDS

Molecular characterization of human T-lymphotropic leukemia virus type III associated with the acquired immunodeficiency syndrome

3 0 -Azido-3 0 -deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1

The interaction of Vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan

Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals

Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis

Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID

Primer ID informs next-generation sequencing platforms and reveals preexisting drug resistance mutations in the HIV-1 reverse transcriptase coding domain

Ultrasensitive single-genome sequencing: accurate, targeted, next generation sequencing of HIV-1 RNA

Linked dual-class HIV resistance mutations are associated with treatment failure

Rates and dates of divergence between AIDS virus nucleotide sequences

Nucleotide substitution rates of HIV-1

Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo

Discovery and genomic characterization of a 382-nucleotide deletion in ORF7b and ORF8 during the early evolution of SARS-CoV-2

On the evolutionary epidemiology of SARS-CoV-2

Temporal signal and the phylodynamic threshold of SARS-CoV-2

Phylogenetic analysis of SARS-CoV-2 in the first few months since its emergence

Infidelity of SARS-CoV nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing

Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity

Advanced molecular assays for SARS-CoV-2

Published by Wolters Kluwer Health

Viral mutation rates

RdRp mutations are associated with SARS-CoV-2 genome evolution

Article showing the distribution of SARS-CoV-2 genetic clades with an outline of potential genomic surveillance objectives. Provides an overview of the three genomic nomenclature systems with informative graphics to help explain the commonalities and differences between systems. 78. (GISAID) GISAID. Clade and lineage nomenclature aids in genomic epidemiology studies of active hCoV-19 viruses

Year-letter genetic clade naming for SARS-CoV-2 on Nextstain

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Genomic evidence for a case of reinfection with SARS-CoV-2

COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

Molecular architecture of early dissemination and massive second wave of the SARS-CoV-2 virus in a major metropolitan area

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

Epub ahead of print

Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID19 patients

Fajnzylber J, Coxen RJ, Corry K, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. medRxiv 2020. Describes an association between SARS-CoV-2 plasma RNA presence and quantity with disease severity.